Showing 81 - 100 results of 270 for search '"ovarian cancer"', query time: 0.09s Refine Results
  1. 81
  2. 82

    STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer by Changli Qian, Gordon J Freeman, Tao Jiang, Ursula Matulonis, Ziying Lin, Hye-Jung Kim, Anniina Färkkilä, Hua Yu, Xin Cheng, Panagiotis A Konstantinopoulos, Antons Martincuks, Joyce F Liu, Qiwei Wang, Liya Ding, Michael J Kearns, Shaozhen Xie, Inga-Maria Launonen, Thomas M Roberts, Jean J Zhao

    Published 2023-01-01
    “…Background Poly (ADP-ribose) polymerase (PARP) inhibition (PARPi) has demonstrated potent therapeutic efficacy in patients with BRCA-mutant ovarian cancer. However, acquired resistance to PARPi remains a major challenge in the clinic.Methods PARPi-resistant ovarian cancer mouse models were generated by long-term treatment of olaparib in syngeneic Brca1-deficient ovarian tumors. …”
    Get full text
    Article
  3. 83
  4. 84

    Effects of Self-Assembled Monolayers with Different Chemical Groups on Ovarian Cancer Cell Line Behavior In Vitro by Jie Li, Ting Guan, Chenjun Hao, Lihua Li, Yu Zhang

    Published 2015-01-01
    “…The current study aimed to investigate the effects of different chemical structures present in the ECM on cellular physiology using the ovarian cancer cell line SKOV-3 as a model. Self-assembled monolayers (SAMs) with different chemical modifications, including methyl (-CH3), hydroxyl (-OH), amino (-NH2), carboxyl (-COOH), and mercapto (-SH) groups, were used as microenvironmental models to explore the effects of different structures on SKOV-3 cells. …”
    Get full text
    Article
  5. 85
  6. 86
  7. 87
  8. 88

    CLDN4 as a Novel Diagnostic and Prognostic Biomarker and Its Association with Immune Infiltrates in Ovarian Cancer by Pan Hu, Li Lei, Ying Wang, Xue Tian, Xia Wei, Ni Jiang, Lubin Liu

    Published 2023-01-01
    “…Ovarian cancer (OC) is the seventh most prevalent type of cancer in women and the second most common cause of cancer-related deaths in women worldwide. …”
    Get full text
    Article
  9. 89
  10. 90
  11. 91
  12. 92
  13. 93

    Prehospital care for ovarian cancer in Catalonia: could we do better in primary care? Retrospective cohort study by Mercè Marzo-Castillejo, Josep M Borras, Carmen Vela-Vallespín, Paula Manchon‐Walsh, Luisa Aliste

    Published 2022-07-01
    “…Objective To assess the impact of prehospital factors (diagnostic pathways, first presentation to healthcare services, intervals, participation in primary care) on 1-year and 5-year survival in people with epithelial ovarian cancer (EOC).Design Retrospective quasi-population-based cohort study.Setting Catalan Integrated Public Healthcare System.Participants People with EOC who underwent surgery with a curative intent in public Catalan hospitals between 1 January 2013 and 31 December 2014.Outcome measures Data from primary and secondary care clinical histories and care processes in the 18 months leading up to confirmation (signs and symptoms at presentation, diagnosis pathways, referrals, diagnosis interval) of the EOC diagnosis (stage, histology type, treatment). …”
    Get full text
    Article
  14. 94

    Contribution of m5C RNA Modification-Related Genes to Prognosis and Immunotherapy Prediction in Patients with Ovarian Cancer by Yibin Liu, Shouze Liu, Lu Yan, Qianqian Zhang, Wenhua Liu, Xianghua Huang, Shikai Liu

    Published 2023-01-01
    “…Here, we established a novel prognostic signature for ovarian cancer (OC) patients based on m5C RNA modification-related genes and explored the correlation between these genes with the tumor immune microenvironment. …”
    Get full text
    Article
  15. 95
  16. 96

    Expression of Semaphorin 3F and Its Receptors in Epithelial Ovarian Cancer, Fallopian Tubes, and Secondary Müllerian Tissues by Christina D. Drenberg, Sandra Livingston, Ren Chen, Patricia A. Kruk, Santo V. Nicosia

    Published 2009-01-01
    “…While semaphorins and their receptors appear to play a role in tumor carcinogenesis, little is known about the role of semaphorin 3F (S3F) in epithelial ovarian cancer (EOC) development. Therefore, we sought to determine the clinical relationship between S3F and its receptors, neuropilin-2 (NP-2) and neuropilin-1 (NP-1) with EOC progression. …”
    Get full text
    Article
  17. 97
  18. 98

    Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer by Kayoko Waki, Kouichiro Kawano, Naotake Tsuda, Kimio Ushijima, Kyogo Itoh, Akira Yamada

    Published 2017-01-01
    “…In the present study, we investigated the plasma levels of HMGB1 during personalized peptide vaccination in patients with recurrent ovarian cancer. Frozen plasma samples of 39 patients from previously conducted clinical trials were used in this study. …”
    Get full text
    Article
  19. 99
  20. 100

    Personality traits of women with hereditary risk for breast/ovarian cancer versus obstetric history and cancer preventive behaviors by Joanna Żurawska, Beata Pięta, Maciej Wilczak, Małgorzata Wojciechowska, Paweł Rzymski, Agnieszka Pieczykolan, Justyna Krysa, Agnieszka Bień

    Published 2025-01-01
    “…Abstract The aim of the study is to analyze the relationship between personality traits of women with hereditary predisposition to breast/ovarian cancer and their obstetric history and cancer-preventive behaviors. …”
    Get full text
    Article